Matinas BioPharma receives contract award from Cystic Fibrosis Foundation Therapeutics
Matinas BioPharma announced it has received a research contract award from Cystic Fibrosis Foundation Therapeutics to study its lead antibiotic product candidate MAT2501, for treatment of pre-clinical nontuberculous mycobacterium infection in models of cystic fibrosis. December 08, 2016